Tuesday , December 12 2017

dave

According to IMS prescribing data, all of the SGLT-2 inhibitor class drugs are experiencing growth. What is more important is that the 6-month adherence rate is higher than any other branded class. Part of this can be attributed to the 2-year free medication vouchers that all manufacturers offer. However, if you look at the data on cardiovascular disease and weight loss in this month’s special edition, you get a good idea as to why prescribers are making this class of drugs their first choice after metformin.

Your partner in diabetes care,
Dave Joffe
Editor-in-chief